01
Commercial
3rd Annual Personalized Cancer Vaccine Summit 2026 | December 1-3, 2026 - pharmaphorum
Summit organizers frame the field at an inflection point: Moderna and Merck have reported positive initial Phase 3 data for intismeran autogene in combination with Keytruda, putting the first regulatory approval of a personalized neoantigen cancer vaccine firmly within sight. The 3rd Annual Personalized Cancer Vaccine Summit (December 1-3, 2026) draws 80+ leaders from Moderna, Medici Therapeutics, Geneos Therapeutics, Nykode Therapeutics, Echo Immune, HDT Bio, Mayo Clinic, and Transgene. The stated agenda — development, manufacturing, delivery, and market access — is a useful proxy for where the industry sees its next bottlenecks now that proof-of-concept is largely settled.